Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37


MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation.

Meyer TJ, Hartmann S, Wohlleben G, Brisam M, Seher A, Kübler AC, Polat B, Müller-Richter UDA.

Mol Clin Oncol. 2018 Mar;8(3):513-519. doi: 10.3892/mco.2018.1558. Epub 2018 Jan 19.


Apoptosis-sensitizing activity of birinapant in head and neck squamous cell carcinoma cell lines.

Brands RC, Scheurer MJJ, Hartmann S, Seher A, Kübler AC, Müller-Richter UDA.

Oncol Lett. 2018 Mar;15(3):4010-4016. doi: 10.3892/ol.2018.7783. Epub 2018 Jan 12.


Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer.

Hartmann S, Zwick L, Maurus K, Fuchs AR, Brands RC, Seher A, Kübler AC, Müller-Richter UDA.

J Craniomaxillofac Surg. 2018 Mar;46(3):492-497. doi: 10.1016/j.jcms.2017.12.014. Epub 2017 Dec 24.


MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer.

Hartmann S, Zwick L, Scheurer MJJ, Fuchs AR, Brands RC, Seher A, Böhm H, Kübler AC, Müller-Richter UDA.

Clin Oral Investig. 2018 Apr;22(3):1477-1486. doi: 10.1007/s00784-017-2242-8. Epub 2017 Oct 15.


The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent.

Lagler C, El-Mesery M, Kübler AC, Müller-Richter UDA, Stühmer T, Nickel J, Müller TD, Wajant H, Seher A.

PLoS One. 2017 Oct 13;12(10):e0185720. doi: 10.1371/journal.pone.0185720. eCollection 2017.


Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro.

Brands RC, Knierim LM, De Donno F, Steinacker V, Hartmann S, Seher A, Kübler AC, Müller-Richter UDA.

Oncol Rep. 2017 Sep;38(3):1877-1885. doi: 10.3892/or.2017.5801. Epub 2017 Jul 10.


Utilizing BMP-2 muteins for treatment of multiple myeloma.

Seher A, Lagler C, Stühmer T, Müller-Richter UDA, Kübler AC, Sebald W, Müller TD, Nickel J.

PLoS One. 2017 May 10;12(5):e0174884. doi: 10.1371/journal.pone.0174884. eCollection 2017.


The prognostic value of GLUT-1 staining in the detection of malignant transformation in oral mucosa.

Brands RC, Köhler O, Rauthe S, Hartmann S, Ebhardt H, Seher A, Linz C, Kübler AC, Müller-Richter UDA.

Clin Oral Investig. 2017 Jun;21(5):1631-1637. doi: 10.1007/s00784-016-1954-5. Epub 2016 Sep 8.


Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion.

Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, Vaeth M, Kuen J, Holtappels R, Podlech J, Mottok A, Kraus S, Jordán-Garrote AL, Bäuerlein CA, Brede C, Ribechini E, Fick A, Seher A, Polz J, Ottmüller KJ, Baker J, Nishikii H, Ritz M, Mattenheimer K, Schwinn S, Winter T, Schäfer V, Krappmann S, Einsele H, Müller TD, Reddehase MJ, Lutz MB, Männel DN, Berberich-Siebelt F, Wajant H, Beilhack A.

J Exp Med. 2016 Aug 22;213(9):1881-900. doi: 10.1084/jem.20151563. Epub 2016 Aug 15.


Evaluation of miRNA-expression and clinical tumour parameters in oral squamous cell carcinoma (OSCC).

Moratin J, Hartmann S, Brands R, Brisam M, Mutzbauer G, Scholz C, Seher A, Müller-Richter U, Kübler AC, Linz C.

J Craniomaxillofac Surg. 2016 Jul;44(7):876-81. doi: 10.1016/j.jcms.2016.04.017. Epub 2016 Apr 22.


Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.

Brands RC, Herbst F, Hartmann S, Seher A, Linz C, Kübler AC, Müller-Richter UDA.

Clin Oral Investig. 2016 Dec;20(9):2325-2332. doi: 10.1007/s00784-016-1741-3. Epub 2016 Feb 4.


Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.

Brands RC, Müller-Richter UD, De Donno F, Seher A, Mutzbauer G, Linz C, Kübler AC, Hartmann S.

Mol Med Rep. 2016 Mar;13(3):2338-44. doi: 10.3892/mmr.2016.4786. Epub 2016 Jan 14.


Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.

Hartmann S, Neckel N, Seher A, Mutzbauer G, Brands RC, Linz C, Kübler AC, Müller-Richter UD.

Clin Oral Investig. 2016 May;20(4):759-69. doi: 10.1007/s00784-015-1566-5. Epub 2015 Aug 23.


Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.

Chopra M, Brandl A, Siegmund D, Mottok A, Schäfer V, Biehl M, Kraus S, Bäuerlein CA, Ritz M, Mattenheimer K, Schwinn S, Seher A, Grabinger T, Einsele H, Rosenwald A, Brunner T, Beilhack A, Wajant H.

Blood. 2015 Jul 23;126(4):437-44. doi: 10.1182/blood-2015-01-620583. Epub 2015 May 26.


MAGE-A expression clusters and antineoplastic treatment in head and neck cancer.

Hartmann S, Meyer TJ, Brands RC, Haubitz IR, Linz C, Seher A, Kübler AC, Müller-Richter UD.

Int J Mol Med. 2015 Jun;35(6):1675-82. doi: 10.3892/ijmm.2015.2174. Epub 2015 Apr 7.


MLN4924 sensitizes monocytes and maturing dendritic cells for TNF-dependent and -independent necroptosis.

El-Mesery M, Seher A, Stühmer T, Siegmund D, Wajant H.

Br J Pharmacol. 2015 Mar;172(5):1222-36. doi: 10.1111/bph.12998. Epub 2015 Jan 13.


Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.

Hartmann S, Seher A, Brands RC, Linz C, Lessner G, Böhm H, Kübler AC, Müller-Richter UD.

J Craniomaxillofac Surg. 2014 Oct;42(7):1322-8. doi: 10.1016/j.jcms.2014.03.018. Epub 2014 Apr 2.


TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK.

Carmona Arana JA, Seher A, Neumann M, Lang I, Siegmund D, Wajant H.

Front Immunol. 2014 Feb 18;5:63. doi: 10.3389/fimmu.2014.00063. eCollection 2014.


Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, Wajant H.

J Biol Chem. 2013 May 10;288(19):13455-66. doi: 10.1074/jbc.M112.435917. Epub 2013 Mar 26.


Novel features of ARS selection in budding yeast Lachancea kluyveri.

Liachko I, Tanaka E, Cox K, Chung SC, Yang L, Seher A, Hallas L, Cha E, Kang G, Pace H, Barrow J, Inada M, Tye BK, Keich U.

BMC Genomics. 2011 Dec 28;12:633. doi: 10.1186/1471-2164-12-633.

Supplemental Content

Support Center